Where Do Potent P2Y12 Inhibitors Fit Into Current Practice? - Acute Coronary Syndrome (ACS)

Published: 24 June 2022

  • Views:

    Views Icon 14380

  • Likes:

    Heart Icon 7
  • episode_image
    9m 31s
    Part 7 Q&A and Discussion
    Robert F Storey, Roxana Mehran, Kurt Huber, Dominick J Angiolillo
  • episode_image
    14m 41s
    Part 1 Unmet Needs in ACS Dominick J Angiolillo, Robert F Storey, Roxana Mehran, Kurt Huber
Average (ratings)
No ratings
Your rating

Overview

This broadcast series 'Where Do Potent P2Y12 Inhibitors Fit Into Current Practice?' will reappraise potent P2Y12 inhibitors, as evidence accumulates to support their broader use. At this juncture, there is still some uncertainty around patient selection, initiation and long-term management.

 

The first broadcast in this series, focused on Acute Coronary Syndrome (ACS). In this on-demand version of the live broadcast, Radcliffe Medical Education brings together a global faculty of experts in the field to look at current guidance, the landmark data, gaps in evidence and seeks to provide practical guidance.

 

Prof Rob Storey (Sheffield University, UK) moderates proceedings, and is joined by Prof Roxana Mehran (Mount Sinai Hospital, US), Prof Dominick Angiolillo (University of Florida College of Medicine-Jacksonville, US) and Prof Kurt Huber (Clinic Ottakring, AT) for a series of insightful presentations and discussions.

 

Catch up now on the other broadcasts in this series:

Chronic Coronary Syndrome (CCS)
Balancing Risk Post-PCI
Stroke Prevention
This broadcast series is supported by an unrestricted educational grant from AstraZeneca.

Key Learning Objectives

  • Recall current unmet needs in ACS
  • Summarise current use of antiplatelet therapy in ACS according to guidelines
  • Describe the mode of action of potent P2Y12 inhibitors
  • Identify settings where a potent P2Y12 inhibitor should be used in favour of clopidogrel
  • Summarise the results of head-to-head trials between clopidogrel and potent P2Y12 inhibitors
  • Select appropriate assessment criteria for ischaemic risk and bleeding risk
  • Identify patients in whom a medical therapy only approach could be used over invasive strategies
  • Use antiplatelet therapy effectively and safely for long-term management of ACS

Target Audience

  • General Cardiologists
  • Interventional Cardiologists
  • Nurses and any other allied HCPs

More from this programme

Part 1

Unmet Needs in ACS

In this first part, Prof Dominick Angiolillo discusses the current unmet needs in antiplatelet therapy, including the requirement for more data around optimal timing of P2Y12 inhibitors, and the need for antiplatelet therapy in long COVID.
1 session
Unmet Needs in ACS Watch now

Part 2

P2Y12 Inhibitors in ACS: The Journey So Far

Prof Kurt Huber provides a whistle-stop tour of P2Y12 inhibitors and how pivotal trials have informed current guidelines recommendations in ACS.
1 session
P2Y12 Inhibitors in ACS: The Journey So Far Watch now

Part 3

Potent P2Y12 Inhibition

Prof Rob Storey provides an in-depth analysis of how potent P2Y12 inhibitors work and take a deep dive on a number of pivotal trials.
1 session
Potent P2Y12 Inhibition Watch now

Part 4

Balancing Efficacy and Risk

Prof Roxana Mehran discusses the different tools for assessing bleeding and ischaemic risk and the relative advantages of individual scores.
1 session
Balancing Efficacy and Risk Watch now

Part 5

Medically Managed ACS

Prof Dominick Angiolillo considers which ACS patients are candidates for non-interventional treatment and how to select an antiplatelet regimen.
1 session
Medically Managed ACS Watch now

Part 6

Long-Term Management

Prof Rob Storey provides an overview of the evidence for long-term use of potent P2Y12 inhibitors and how to deal with adverse events.
1 session
Long-Term Management Watch now

Part 7

Q&A and Discussion

In this final chapter, Prof Rob Storey addresses questions received by the audience to our panel.
1 session
Q&A and Discussion Watch now

Faculty Biographies

Roxana Mehran

Roxana Mehran

Professor of Medicine, Cardiology and Professor of Population Health Science and Policy

Roxana Mehran is Professor of Medicine, Cardiology and Professor of Population Health Science and Policy at the Icahn School of Medicine at Mount Sinai in New York. She is also Director of Interventional Cardiovascular Research and Clinical Trials at The Zena and Michael A Weiner Cardiovascular Institute at Mount Sinai Hospital where, over the past 5 years, she has led the development of a globally respected data and clinical coordination centre to support large, multicentre, multinational clinical trials designed to help improve outcomes and quality of life for patients undergoing interventional cardiovascular procedures. In recent years, her work has had a special emphasis on gaining a deeper understanding of anticoagulation and antiplatelet regimens post angioplasty and transcatheter valve replacement; and collection and interpretation of sex-specific data in cardiovascular clinical trials.

Roxana serves on editorial board of multiple peer reviewed journals, including …

View full profile